148 related articles for article (PubMed ID: 30916600)
1. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.
Berkhout A; Clark JE; Wen SC
Expert Rev Vaccines; 2019 May; 18(5):495-504. PubMed ID: 30916600
[TBL] [Abstract][Full Text] [Related]
2. Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation.
Dinelli MIS; Dos Santos AMN; Weckx LY; de Moraes-Pinto MI
Transpl Infect Dis; 2018 Oct; 20(5):e12951. PubMed ID: 29890028
[TBL] [Abstract][Full Text] [Related]
3. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America.
Tregnaghi MW; Abate HJ; Valencia A; Lopez P; Da Silveira TR; Rivera L; Rivera Medina DM; Saez-Llorens X; Gonzalez Ayala SE; De León T; Van Doorn LJ; Pilar Rubio MD; Suryakiran PV; Casellas JM; Ortega-Barria E; Smolenov IV; Han HH;
Pediatr Infect Dis J; 2011 Jun; 30(6):e103-8. PubMed ID: 21378594
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
Steele AD; Reynders J; Scholtz F; Bos P; de Beer MC; Tumbo J; Van der Merwe CF; Delem A; De Vos B
J Infect Dis; 2010 Sep; 202 Suppl():S93-100. PubMed ID: 20684724
[TBL] [Abstract][Full Text] [Related]
5. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
[TBL] [Abstract][Full Text] [Related]
6. Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule.
Saleh E; Eichner B; Clark DW; Gagliano ME; Troutman JM; Harrington L; McNeal M; Clements D
J Pediatric Infect Dis Soc; 2018 Feb; 7(1):82-85. PubMed ID: 28340179
[TBL] [Abstract][Full Text] [Related]
7. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
[TBL] [Abstract][Full Text] [Related]
8. Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.
Aliabadi N; Tate JE; Parashar UD
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5(Suppl 5):S128-S135. PubMed ID: 27129416
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.
Dang DA; Nguyen VT; Vu DT; Nguyen TH; Nguyen DM; Yuhuan W; Baoming J; Nguyen DH; Le TL;
Vaccine; 2012 Apr; 30 Suppl 1():A114-21. PubMed ID: 22520120
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.
Goveia MG; Suprun L; Itzler RF; McFetridge R; Dallas MJ; Kuter BJ
Pediatr Infect Dis J; 2010 Mar; 29(3):263-5. PubMed ID: 19949360
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants.
Saluja T; Palkar S; Misra P; Gupta M; Venugopal P; Sood AK; Dhati RM; Shetty A; Dhaded SM; Agarkhedkar S; Choudhury A; Kumar R; Balasubramanian S; Babji S; Adhikary L; Dupuy M; Chadha SM; Desai F; Kukian D; Patnaik BN; Dhingra MS
Vaccine; 2017 Jun; 35(28):3575-3581. PubMed ID: 28536027
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007.
Anh DD; Carlos CC; Thiem DV; Hutagalung Y; Gatchalian S; Bock HL; Smolenov I; Suryakiran PV; Han HH
Vaccine; 2011 Mar; 29(11):2029-36. PubMed ID: 21256876
[TBL] [Abstract][Full Text] [Related]
14. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.
Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA
Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118
[TBL] [Abstract][Full Text] [Related]
15. Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.
Cowley D; Boniface K; Bogdanovic-Sakran N; Kirkwood CD; Bines JE
Hum Vaccin Immunother; 2017 Aug; 13(8):1908-1915. PubMed ID: 28481726
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus vaccines: targeting the developing world.
Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
[TBL] [Abstract][Full Text] [Related]
17. Rotavirus: disease and vaccine update, 2007.
Stebbins S
J Fam Pract; 2007 Feb; 56(2 Suppl Vaccines):S6-11. PubMed ID: 17270111
[TBL] [Abstract][Full Text] [Related]
18. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of rotavirus vaccines in Europe.
Vesikari T; Giaquinto C; Huppertz HI
Pediatr Infect Dis J; 2006 Jan; 25(1 Suppl):S42-7. PubMed ID: 16397428
[TBL] [Abstract][Full Text] [Related]
20. [Rotavirus Vaccine. Statement of the Consultive Committee of Immunizations on behalf of The Chilean Infectious Diseases Society. March 2006].
Muñoz M A; Abarca V K; Luchsinger F V; Valenzuela B MT; Jiménez de la J J;
Rev Chilena Infectol; 2006 Jun; 23(2):124-7. PubMed ID: 16721445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
